Upfront surgery vs. neoadjuvant therapy in pancreatic cancer with venous involvement: a multicenter retrospective analysis - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Comparative Analysis of Initial Surgical Intervention versus Neoadjuvant Treatment in Pancreatic Cancer with Venous Involvement: A Multicenter Retrospective Study

  • By

  • Asif Halimi

  • Eline S. Zwart

  • Bengi S. Yilmaz

  • Benediktas Kurlinkus

  • Reea Ahola

  • Marco Del Chiaro

  • Ernesto Sparrelid

  • Elena Rangelova

  • Laura Maggino

  • Giuseppe Malleo

  • Gabriella Lionetto

  • Roberto Salvia

  • Keith J. Roberts

  • Francesco Giovinazzo

  • Massimo Falconi

  • Stefano Crippa

  • Giulio Belfiori

  • Geert Kazemier

  • Patrick Maisonneuve

  • Johanna Laukkarinen

  • Güralp O. Ceyhan

  • September 22, 2026

Share

  • 1

    Pancreatic cancer often presents with metastatic disease, with only 10-15% of cases suitable for primary resection.

  • 2

    The management of venous involvement in pancreatic cancer remains controversial, with differing guidelines on neoadjuvant therapy versus upfront surgery.

  • 3

    This study analyzed outcomes in 690 patients undergoing upfront surgery and 361 receiving neoadjuvant therapy before pancreatic resection.

  • 4

    Patients in the upfront surgery group had more advanced tumors and higher rates of complications compared to those receiving neoadjuvant therapy.

  • 5

    The study found that radical resection was achieved less frequently in the upfront surgery group, indicating potential differences in treatment outcomes.

Original Source(s)

Upfront surgery vs. neoadjuvant therapy in pancreatic cancer with venous involvement: a multicenter retrospective analysis

  • by Asif Halimi, Eline S. Zwart, Bengi S. Yilmaz, Benediktas Kurlinkus, Reea Ahola, Marco Del Chiaro, Ernesto Sparrelid, Elena Rangelova, Laura Maggino, Giuseppe Malleo, Gabriella Lionetto, Roberto Salvia, Keith J. Roberts, Francesco Giovinazzo, Massimo Falconi, Stefano Crippa, Giulio Belfiori, Geert Kazemier, Patrick Maisonneuve, Johanna Laukkarinen, Güralp O. Ceyhan

  • September 22, 2026

Related Content

Parents’ Perspectives on Using Computerized Cognitive Training to Manage Cognitive Late Effects in Children With Cancer: Qualitative Descriptive Study

Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis

Revised Meta-Analysis After Exclusion of Retracted Study

  • October 21, 2026